Clinical Trials Logo

Clinical Trial Summary

This study will involve measurement of levels of a novel urinary biomarker of renal ischemia, L-FABP. The purpose of the study is to perform a clinical validation of the ability of L-FABP measurements in urine using the RENISCHEM L-FABP POC Test to predict the development of AKI within 2 days following cardiac and vascular catheterization procedures involving exposure to radiocontrast media.


Clinical Trial Description

This study will validate the ability of the RENISCHEM L-FABP POC test to predict AKI risk in patients undergoing cardiac catheterization and receiving iodinated contrast medium. Contrast medium is known to be both vasoconstrictive and chemotoxic, which can lead to renal ischemia and, ultimately, AKI. Infusion of radiographic contrast agents, with the associated increases in osmotic load and viscosity, increases hypoxia of the renal medulla and increases renal free radical production through post-ischemic oxidative stress. Earlier identification of contrast medium-induced acute kidney injury (CI-AKI) risk can facilitate improved management of patients to prevent AKI, for example, through selection of alternative imaging methods or contrast agents. Subjects will be recruited prospectively based on pre-specified enrollment criteria. Blood and urine samples will be collected after enrollment and at several timepoints, and various tests will be performed, including point-of-care L-FABP measurements on urine samples. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04864847
Study type Observational
Source Hikari Dx, Inc.
Contact Jeffrey Dahlen, Ph.D.
Phone (619) 742-0203
Email [email protected]
Status Not yet recruiting
Phase
Start date May 31, 2021
Completion date December 31, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT03938038 - Guidance of Ultrasound in Intensive Care to Direct Euvolemia N/A
Recruiting NCT04293744 - Acute Kidney Injury After Cardiac Surgery; A Prospective Randomized Study of Dextran Based and Crystalloid Priming Solutions N/A
Recruiting NCT04095143 - Ultrasound Markers of Organ Congestion in Severe Acute Kidney Injury
Recruiting NCT03438877 - Intensive Versus Regular Dosage For PD In AKI. N/A
Terminated NCT03305549 - Recovery After Dialysis-Requiring Acute Kidney Injury N/A
Enrolling by invitation NCT04062994 - A Clinical Decision Support Trial to Reduce Intraoperative Hypotension
Terminated NCT02860130 - Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT) Phase 3
Recruiting NCT02665377 - Prevention of Akute Kidney Injury, Hearttransplant, ANP Phase 3
Recruiting NCT03539861 - Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients N/A
Not yet recruiting NCT04523064 - iSGLT2 in Prevention of Acute Kidney Injury in Patients With Diabetes Mellitus Undergoing CABG Extracorporeal On-Pump Phase 4
Recruiting NCT02976792 - Effectiveness of the NephroCheck™ After TAVI N/A
Recruiting NCT02518087 - Increased Adsorption Membranes During Cardiopulmonary Bypass N/A
Recruiting NCT02914782 - Investigation of Fluid- and Electrolyte Balance in Post Cardiac-surgery Patients
Active, not recruiting NCT01720030 - Levosimendan in Acute Kidney Injury Study Phase 2/Phase 3
Active, not recruiting NCT02533609 - Elimination of Antibiotics During Citrate-anticoagulated Continuous-veno-venous-haemodialysis
Active, not recruiting NCT02483039 - Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization N/A
Completed NCT02675296 - Regional and Long Term Outcomes of Acute Kidney Injury in England From 2000 to 2015 - A National Database Study N/A
Completed NCT02531724 - Effects of Levosimendan in Acute Kidney Injury After Cardiac Surgery Phase 4
Completed NCT02554253 - The Impact of Ketamine on Postoperative Cognitive Dysfunction, Delirium, and Renal Dysfunction N/A
Recruiting NCT02338895 - Algorithm for Oliguria in Septic Shock N/A